Drug Profile


Alternative Names: BAF-312

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Immunosuppressants; Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II Dermatomyositis; Polymyositis
  • Phase I Liver failure; Renal failure

Most Recent Events

  • 01 Feb 2017 Novartis Pharmaceuticals terminates a phase II trial in Polymyositis in USA, Belgium, Czech Republic, Hungary, Taiwan, Canada and Poland (NCT01801917)
  • 01 Oct 2016 Novartis completes the phase II BOLD EXTENSION trial in Multiple sclerosis in USA, Canada, Finland, Germany, Hungary, Italy, Norway, Poland, Russia, Spain, Switzerland, Turkey (NCT01185821)
  • 17 Sep 2016 Adverse events and efficacy data from the phase III EXPAND trial in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top